Project Description

Hypophosphatemia: The word hypophosphatemia means a low serum phosphorus concentration. If hypophosphatemia is chronic and is also accompanied by phosphaturia (phosphorus in the urine), it may be due to either the kidney’s reduced capacity to excrete acid (called renal tubular acidosis) or to the presence of an elevated protein in the blood that causes the kidney to waste phosphorus (Fibroblast Growth Factor 23-FGF 23).

FGF 23 is normally made in another bone cell, the osteocyte. However, the medical condition that may lead to fractures, muscle pain and weakness is an excess production of FGF 23 from small, mostly benign tumors and given the diagnostic label, tumor-induced-osteomalacia (TIO) since these patients also develop osteomalacia. If the tumor can be found by very specialized radiological procedures, removal of the tumor cures the condition, since the source of the excess FGF 23 is removed.

If the tumor cannot be found, a new pharmacological therapy recently FDA approved is available called Burosemide™( a monoclonal antibody directed against FGF 23).